Demyelination: The Role of Reactive Oxygen and Nitrogen Species

Brain Pathology - Tập 9 Số 1 - Trang 69-92 - 1999
Kenneth J. Smith1, Raju Kapoor1,2, Paul A. Felts1
1Department of Clinical Neurological Sciences, Guy's, King's and St. Thomas' School of Medicine, Hodgkin Building, Guy's Campus, St. Thomas St., London, SE1 9RT
2The National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 3BG

Tóm tắt

This review summarises the role that reactive oxygen and nitrogen species play in demyelination, such as that occurring in the inflammatory demyelinating disorders multiple sclerosis and Guillain‐Barré syndrome. The concentrations of reactive oxygen and nitrogen species (e.g. superoxide, nitric oxide and peroxynitrite) can increase dramatically under conditions such as inflammation, and this can overwhelm the inherent antioxidant defences within lesions. Such oxidative and/or nitrative stress can damage the lipids, proteins and nucleic acids of cells and mitochondria, potentially causing cell death. Oligodendrocytes are more sensitive to oxidative and nitrative stress in vitro than are astrocytes and microglia, seemingly due to a diminished capacity for antioxidant defence, and the presence of raised risk factors, including a high iron content. Oxidative and nitrative stress might therefore result in vivo in selective oligodendrocyte death, and thereby demyelination. The reactive species may also damage the myelin sheath, promoting its attack by macrophages. Damage can occur directly by lipid peroxidation, and indirectly by the activation of proteases and phospholipase A2. Evidence for the existence of oxidative and nitrative stress within inflammatory demyelinating lesions includes the presence of both lipid and protein peroxides, and nitrotyrosine (a marker for peroxynitrite formation). The neurological deficit resulting from experimental autoimmune demyelinating disease has generally been reduced

Từ khóa


Tài liệu tham khảo

QG AN, 1997, Neurotoxicity and possible roles of aspartic acid, glutamic acid and GABA in some neurologic disorders, Biogenic Amines, 13, 565

Ali QG, 1996, Multiple sclerosis and neurotransmission, Biogenic Amines, 12, 353

10.1021/tx950133b

10.1111/j.1600-0404.1986.tb04643.x

10.1016/0006-8993(78)90300-1

10.1096/fasebj.10.10.8751715

10.1523/JNEUROSCI.18-16-06241.1998

10.1073/pnas.92.26.12041

10.1093/brain/114.3.1271

10.1016/0002-9343(91)90278-6

10.1016/S0079-6123(08)61151-6

10.1152/ajpcell.1996.271.5.C1424

10.1523/JNEUROSCI.18-05-01633.1998

10.1097/00000658-199504000-00003

10.1002/glia.440080108

10.1159/000109543

10.1002/ana.410360515

10.1016/0006-8993(92)91004-X

10.1046/j.1471-4159.1997.68062227.x

10.1016/S0891-5849(96)00240-7

10.1046/j.1471-4159.1994.63030910.x

10.1038/368850a0

10.1016/0891-5849(93)90144-J

10.1002/jnr.490410209

10.1007/BF00973097

10.1046/j.1471-4159.1995.65031342.x

10.1016/0165-5728(95)00061-6

10.1084/jem.160.5.1532

10.1016/S0891-5849(96)00404-2

Brenner T, 1997, Inhibition of nitric oxide synthase for treatment of experimental autoimmune encephalomyelitis, J Immunol, 158, 2940, 10.4049/jimmunol.158.6.2940

10.1159/000112102

10.1016/0304-3940(95)11703-Y

10.1002/ana.410350111

10.1016/0014-5793(95)00401-T

Calabrese V, 1995, Changes in cerebrospinal fluid levels of malondialdehyde and glutathione reductase activity in multiple sclerosis. Intern, J Clin Pharm Res, 14, 119

10.1002/ana.410370404

10.1136/bmj.2.5552.610

10.1016/0304-3940(95)12173-0

10.1161/01.RES.76.3.325

10.1016/0925-4439(93)90078-F

10.1172/JCI115929

10.1016/0304-3940(95)12101-9

10.1007/BF02815200

10.1016/0960-5428(95)00031-3

10.1152/ajpcell.1994.266.6.C1650

10.1111/j.1749-6632.1994.tb21789.x

10.1111/j.1749-6632.1994.tb21789.x

10.1159/000112115

10.1002/jnr.490170108

10.1002/jnr.490270421

10.1016/S0306-9877(97)90196-1

CorkillDJ WoolleyK GuardS WrightA GallowayWA ThomasSW AskewM BeckettP DavisMH MillerK StablerG GearingA WoodLM(1995)The effect of a novel inhibitor of tumour necrosis factor a (TNFα) processing BB‐1101 in experimental autoimmune encephalomyelitis.Br J Pharmacol8P..

10.1002/eji.1830211036

10.1016/S0165-5728(98)00040-X

10.1016/S0165-5728(96)00147-6

10.1016/S0165-5728(98)00078-2

10.1016/S0165-5728(97)00145-8

10.1172/JCI117282

10.1007/978-1-4757-9480-9_21

10.1016/0197-0186(94)00168-T

10.1002/ana.410370122

10.1097/00005072-199701000-00002

Vries HE, 1997, The blood‐brain barrier in neuroinflammatory diseases, Pharmacol Rev, 49, 143

10.1046/j.1365-2125.1996.03804.x

10.1111/j.1365-2249.1992.tb06430.x

10.1016/0028-3908(93)90096-L

10.4049/jimmunol.160.6.2560

10.1046/j.1471-4159.1997.68051896.x

10.1016/0167-5699(95)80080-8

10.1016/0197-0186(94)00164-P

10.1016/0891-0618(95)00140-9

Fenyk‐Melody JE, 1998, Experimental autoimmune encephalomyelitis is exacerbated in mice lacking the NOS2 gene, J Immunol, 160, 2940, 10.4049/jimmunol.160.6.2940

10.1007/BF00916395

10.1146/annurev.ph.57.030195.003343

10.1002/ana.410260115

10.1172/JCI117578

10.1002/jnr.490360409

Ginsberg MD, 1979, Delayed neurological deterioration following hypoxia, Adv Neurol, 26, 21

10.1001/archneur.1976.00500010007002

10.1191/135245898678909178

10.1111/j.1600-0404.1993.tb04212.x

10.1006/cimm.1996.0050

Gopalakrishna R, 1993, Nitric oxide and nitric oxide‐generating agents induce a reversible inactivation of protein kinase C activity and phorbol ester binding, J Biol Chem, 268, 27180, 10.1016/S0021-9258(19)74235-5

10.1016/0014-5793(93)80269-Z

10.1093/carcin/17.11.2501

Griot C, 1989, Makrophagen bei der zentralnervosen Hundestaupe: Freunde Oder Feinde, Schweizer Archiv Tierheilk, 131, 351

10.1007/BF00688176

10.3109/10715769009088915

10.1016/S0165-5728(96)00159-2

10.1016/S0165-5728(97)00172-0

10.1007/BF02937555

10.1016/0014-5793(86)80626-3

10.1159/000267321

10.1159/000267494

10.1002/ana.410320724

10.1016/0006-8993(88)90782-2

10.1016/S0166-2236(96)10071-0

Halliwell B, 1998, Free Radicals in Biology and Medicine

10.1016/0165-5728(95)00104-A

10.1002/ana.410230505

10.1007/BF00227672

10.1016/0304-3940(93)90898-U

10.1007/BF01796266

10.1084/jem.170.2.607

10.1073/pnas.94.6.2528

10.1073/pnas.92.12.5312

10.1073/pnas.95.2.675

10.1002/glia.440150412

10.1002/ana.410430317

10.3109/10715769309145868

10.1007/BF00988606

10.1016/0006-8993(95)00832-B

10.1016/0306-9877(93)90052-R

10.2169/internalmedicine.34.734

10.1016/0003-9861(92)90431-U

Janabi N, 1996, Endogenous nitric oxide activates prostaglandin F2 alpha production in human microglial cells but not in astrocytes: a study of interactions between eicosanoids, nitric oxide, and superoxide anion (O2‐) regulatory pathways, J Immunol, 157, 2129, 10.4049/jimmunol.157.5.2129

10.1016/S0361-9230(98)00052-5

Jensen GE, 1986, Glutathione peroxidase activity, associated enzymes and substrates in blood cells from patients with multiple sclerosis ‐ effects of antioxidant supplementation, Acta Pharmacol Toxicol, 59, 450, 10.1111/j.1600-0773.1986.tb02800.x

10.1136/jnnp.58.1.107

10.1016/S0149-7634(96)00005-X

10.1002/(SICI)1098-1136(199804)22:4<371::AID-GLIA6>3.0.CO;2-6

10.1093/brain/120.4.647

10.1016/0014-5793(93)81483-G

10.1002/jnr.490290111

10.1001/archneur.1991.00530140091021

10.1016/S0304-3940(97)00235-8

10.1111/j.1600-0404.1997.tb00076.x

10.1523/JNEUROSCI.18-03-01038.1998

10.1111/j.1471-4159.1985.tb05530.x

10.1073/pnas.90.7.3024

10.1073/pnas.88.11.4651

10.1159/000116835

10.1016/S0006-8993(97)00470-8

10.1016/S0891-5849(98)00019-7

10.1016/S0896-6273(00)80484-5

10.1084/jem.178.2.643

10.1002/ana.410360309

Liu J, 1996, Expression of type II nitric oxide synthase in primary human astrocytes and microglia: role of IL‐1 beta and IL‐1 receptor antagonist, J Immunol, 157, 3569, 10.4049/jimmunol.157.8.3569

10.1016/0891-5849(95)02147-7

10.1515/bchm.1998.379.2.193

10.1006/cimm.1997.1091

Marchetti P, 1996, Mitochondrial permeability transition triggers lymphocyte apoptosis, J Immunol, 157, 4830, 10.4049/jimmunol.157.11.4830

10.1161/01.RES.76.3.426

10.1073/pnas.91.16.7496

Merrill JE, 1993, Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide, J Immunol, 151, 2132, 10.4049/jimmunol.151.4.2132

10.1073/pnas.89.2.574

10.1006/brbi.1997.0496

10.1002/(SICI)1097-4547(19970515)48:4<372::AID-JNR9>3.0.CO;2-8

10.1007/BF00916935

10.1007/BF00296104

10.1016/S0301-0082(97)00052-X

10.1002/(SICI)1098-1136(199702)19:2<152::AID-GLIA6>3.0.CO;2-2

10.1016/0306-4522(94)90435-9

10.1016/0306-4522(94)00491-M

10.1006/bbrc.1993.1221

10.1093/brain/119.1.225

10.1007/BF02527713

Naidoo R, 1992, Studies of lipid peroxidation products in cerebrospinal fluid and serum in multiple sclerosis and other conditions, Clin Chem, 38, 2449, 10.1093/clinchem/38.12.2449

10.1016/0197-0186(94)00169-U

10.1016/0076-6879(91)05120-K

10.1016/S0021-9258(17)36703-0

10.1093/brain/119.1.213

10.1111/j.1365-2990.1996.tb00900.x

10.1111/j.1365-2990.1994.tb01174.x

10.1016/0006-8993(94)91525-3

10.1523/JNEUROSCI.13-04-01441.1993

10.1016/0165-5728(95)00114-H

10.1073/pnas.89.18.8676

Owens MW, 1997, Effects of reactive metabolites of oxygen and nitrogen on gelatinase A activity, Am J Physiol, 273, L445

10.1006/bbrc.1994.1766

10.1007/s001090050102

10.1016/S0165-5728(97)00256-7

10.1016/S0301-0082(97)00010-5

10.1016/0891-5849(95)00168-W

10.1002/(SICI)1098-1136(199804)22:4<408::AID-GLIA10>3.0.CO;2-#

10.1002/ana.410330203

10.1002/ana.410050105

Qureshi GA, 1993, Role of neurotransmitter amino acids in multiple sclerosis in exacerbation, remission and chronic progressive course, Biogenic Amines, 10, 39

10.1016/0003-9861(91)90224-7

10.1016/S0021-9258(20)64313-7

10.1097/00005072-199305000-00003

10.1016/0165-5728(94)90238-0

10.1093/brain/120.12.2149

10.1093/brain/120.10.1895

10.1016/S0268-9499(97)80029-X

10.1016/S0167-7306(08)60441-X

10.1016/S0006-8993(97)01543-6

10.1016/0891-5849(95)02183-3

10.1016/S0165-5728(97)00162-8

10.1016/S0021-9258(18)47160-8

10.1212/WNL.49.2.358

10.1016/0165-5728(94)00154-G

10.1111/j.1365-2249.1996.tb08304.x

10.1111/j.1471-4159.1993.tb09802.x

Sahrbacher UC, 1998, Mice with an inactivation of the inducible nitric oxide synthase gene are susceptible to experimental autoimmune encephalomyelitis. Eur, J Immunol, 28, 1330

10.1006/abbi.1998.0658

10.1016/S0165-5728(97)00136-7

10.1212/WNL.30.3.323

10.1002/j.1460-2075.1993.tb05978.x

10.1042/bst025166s

10.1172/JCI115102

10.1002/(SICI)1098-1136(199712)21:4<370::AID-GLIA4>3.0.CO;2-7

10.1111/j.1550-7408.1991.tb04435.x

10.1152/jn.1998.79.2.529

10.1111/j.1600-0404.1977.tb01459.x

10.1111/j.1471-4159.1992.tb08328.x

10.1111/j.1460-9568.1993.tb00934.x

10.1046/j.1471-4159.1996.66031227.x

10.1046/j.1471-4159.1995.65010041.x

10.1016/0006-8993(87)90712-8

10.1038/eye.1994.51

10.1177/107385849700300411

Smith KJ, 1998, Nitric oxide donors cause persistent axonal damage: electrically active axons are especially susceptible, Soc Neurosci Abstr, 737, 2

10.1016/0022-510X(82)90168-X

Springfield JR, 1994, Pitfalls in the use of breath pentane measurements to assess lipid peroxidation, J Lipid Res, 35, 1497, 10.1016/S0022-2275(20)40091-4

10.1152/ajpcell.1991.260.5.C910

10.1073/pnas.89.1.444

10.1046/j.1471-4159.1997.68062547.x

10.1046/j.1471-4159.1998.70010432.x

10.1016/0165-5728(93)90178-2

10.1046/j.1365-2362.1997.2250774.x

10.1097/00001756-199707070-00030

10.1016/S0165-5728(98)00124-6

10.1006/viro.1995.0021

10.1016/0891-5849(96)00170-0

10.1016/0361-9230(96)00159-1

10.1046/j.1471-4159.1994.63010266.x

10.1002/eji.1830240430

Thorn SR, 1990, Carbon monoxide‐mediated brain lipid peroxidation in the rat, J Appl Physiol, 68, 997, 10.1152/jappl.1990.68.3.997

10.1046/j.1471-4159.1996.67031014.x

10.1007/BF00966801

10.1056/NEJM199801293380502

10.1016/0022-510X(88)90130-X

10.1146/annurev.bi.61.070192.001105

10.1016/S0165-5728(97)00013-1

10.1016/0006-8993(93)91003-B

10.1002/(SICI)1098-1136(199703)19:3<190::AID-GLIA2>3.0.CO;2-3

10.1084/jem.178.2.605

10.1007/BF00294175

Warren J, 1978, Oxygen immunosuppression: modification of experimental allergic encephalomyelitis in rodents, J Immunol, 121, 315, 10.4049/jimmunol.121.1.315

10.1016/1044-0305(95)00709-1

10.1016/0306-9877(94)90070-1

10.1016/0022-510X(80)90088-X

10.1016/0165-5728(88)90020-3

10.1139/y97-146

10.1074/jbc.272.17.11147

10.1073/pnas.90.21.9813

10.1126/science.1948068

10.1016/S0891-5849(98)00092-6

10.1016/0092-8674(89)90944-6

Woodroofe MN, 1989, Fc receptor density, MHC antigen expression and superoxide production are increased in interferon‐gamma‐treated microglia isolated from adult rat brain, Immunology, 68, 421

10.1073/pnas.93.13.6770

10.1016/0022-510X(96)00164-5

10.1016/S0022-510X(97)00183-4

10.1097/00001756-199609020-00025

10.1046/j.1471-4159.1996.67020566.x

10.1016/0304-3940(95)11490-N

10.1093/brain/114.6.2437

10.1615/CritRevNeurobiol.v10.i3-4.20

10.1084/jem.182.2.367

10.1016/0165-5728(95)00158-1

10.1016/0165-5728(94)00192-Q

10.1016/0304-3940(94)11187-N

10.1016/0008-8749(92)90131-8